Key result
Review highlights comparative cardioprotective properties of NOACs and nattokinase beyond standard anticoagulation.
Why the study?
To elucidate the comparative cardioprotective efficacy of NOACs and nattokinase beyond anticoagulation by combining basic research and clinical findings.
What are the comparative cardioprotective efficacies of NOACs and nattokinase in modern cardiovascular care?
What are the comparative cardioprotective efficacies of NOACs and nattokinase in modern cardiovascular care?
This narrative review summarizes the potential cardioprotective benefits of nattokinase, a natural enzyme, compared to synthetic NOACs, highlighting its fibrinolytic, antihypertensive, and anti-atherosclerotic properties.
Nattokinase's adjunctive role remains hypothesis-generating; leaves open need for RCTs versus NOACs before any clinical consideration.
The use of non-vitamin K antagonist oral anticoagulants (NOACs) has brought a significant progress in the management of cardiovascular diseases, considered clinically superior to vitamin K antagonists (VKAs) particularly in the prevention and treatment of thromboembolic events. In addition, numerous advantages such as fixed dosing, lack of laboratory monitoring, and fewer food and drug-to-drug interactions make the use of NOACs superior to VKAs. While NOACs are synthetic drugs prescribed for specific conditions, nattokinase (NK) is a natural enzyme derived from food that has potential health benefits. Various experimental and clinical studies reported the positive effects of NK on the circulatory system, including the thinning of blood and the dissolution of blood clots. This enzyme showed not only fibrinolytic activity due to its ability to degrade fibrin, but also an affinity as a substrate for plasmin. Recent studies have shown that NK has additional cardioprotective effects, such as antihypertensive and anti-atherosclerotic effects. In this narrative review, we presented the cardioprotective properties of two different approaches that go beyond anticoagulation: NOACs and NK. By combining evidence from basic research with clinical findings, we aim to elucidate the comparative cardioprotective efficacy of these interventions and highlight their respective roles in modern cardiovascular care.
No takes yet. Share an insight, caveat, or question.
Muric et al. (2024) conducted a review in Cardiovascular diseases. NOACs and Nattokinase was evaluated on Cardioprotective efficacy. This narrative review highlights the comparative cardioprotective properties of NOACs and nattokinase, emphasizing their respective roles in modern cardiovascular care beyond anticoagulation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: